A Multicenter, Open-Label Phase 1 Study of DS-1205c in Combination With Osimertinib in Subjects With Metastatic or Unresectable EGFR-Mutant Non-Small Cell Lung Cancer
Phase of Trial: Phase I
Latest Information Update: 22 Oct 2019
Price : $35 *
At a glance
- Drugs DS 1205 (Primary) ; Osimertinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Daiichi Sankyo Inc
- 16 Oct 2019 Planned number of patients changed from 18 to 21.
- 10 Apr 2019 Planned number of patients changed from 118 to 18.
- 10 Apr 2019 Planned End Date changed from 15 Oct 2020 to 15 Jun 2021.